Zhende Medical(SH:603301) Xin Lang Cai Jing·2026-02-03 01:29Core Viewpoint - Zhendemedical experienced a decline of 2.37% on February 2, with a trading volume of 87.14 million yuan, indicating a potential market reaction to recent financial performance and trading activity [1]. Financing Summary - On February 2, Zhendemedical had a financing buy-in amount of 14.04 million yuan, with a net financing buy of 7.70 million yuan, reflecting strong investor interest despite the stock price drop [1]. - The total financing and securities balance reached 1.41 billion yuan, accounting for 7.89% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of leverage [1]. - The company had no shares repaid in the securities lending market on February 2, with 100 shares sold, resulting in a selling amount of 6,714 yuan, and a securities lending balance of 1.03 million yuan, also above the 80th percentile of the past year [1]. Financial Performance - For the period from January to September 2025, Zhendemedical reported a revenue of 3.18 billion yuan, representing a year-on-year growth of 1.88%, while the net profit attributable to shareholders decreased by 33.91% to 203 million yuan [2]. - The company has distributed a total of 1.46 billion yuan in dividends since its A-share listing, with 706 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Zhendemedical had 23,600 shareholders, an increase of 4.06% from the previous period, with an average of 11,308 circulating shares per shareholder, a decrease of 3.90% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked fourth with an increase of 190,000 shares, while the fund "Zhaoshang Core Competitiveness Mixed A" exited the top ten list [3].